Korman Howard J, Mathur Mohit, Luke Natalie, Wang Dakun, Zhao Xihua, Levin Michael, Wenzler David L, Baunoch David
Comprehensive Urology Division, Michigan Healthcare Professionals, Royal Oak, MI, USA.
Department of Medical Affairs, Pathnostics, Irvine, CA, USA.
Infect Drug Resist. 2023 May 9;16:2841-2848. doi: 10.2147/IDR.S406745. eCollection 2023.
To compare antibiotic resistance results at different time points in patients with urinary tract infections (UTIs), who were either treated based upon a combined multiplex polymerase chain reaction (M-PCR) and pooled antibiotic susceptibility test (P-AST) or were not treated.
The M-PCR/P-AST test utilized here detects 30 UTI pathogens or group of pathogens, 32 antibiotic resistance (ABR) genes, and phenotypic susceptibility to 19 antibiotics. We compared the presence or absence of ABR genes and the number of resistant antibiotics, at baseline (Day 0) and 5-28 days (Day 5-28) after clinical management in the antibiotic-treated (n = 52) and untreated groups (n = 12).
Our results demonstrated that higher percentage of patients had a reduction in ABR gene detection in the treated compared to the untreated group (38.5% reduction vs 0%, = 0.01). Similarly, significantly more patients had reduced numbers of resistant antibiotics, as measured by the phenotypic P-AST component of the test, in the treated than in the untreated group (42.3% reduction vs 8.3%, = 0.04).
Our results with both resistance gene and phenotypic antibiotic susceptibility results demonstrated that treatment based upon rapid and sensitive M-PCR/P-AST resulted in reduction rather than induction of antibiotic resistance in symptomatic patients with suspected complicated UTI (cUTI) in an urology setting, indicating this type of test is valuable in the management of these types of patients. Further studies of the causes of gene reduction, including elimination of ABR gene-carrying bacteria and loss of ABR gene(s), are warranted.
比较基于多重聚合酶链反应(M-PCR)和混合抗生素敏感性试验(P-AST)联合检测进行治疗或未接受治疗的尿路感染(UTI)患者在不同时间点的抗生素耐药结果。
此处使用的M-PCR/P-AST检测可检测30种UTI病原体或病原体组、32种抗生素耐药(ABR)基因以及对19种抗生素的表型敏感性。我们比较了抗生素治疗组(n = 52)和未治疗组(n = 12)在基线(第0天)以及临床治疗后5 - 28天(第5 - 28天)ABR基因的有无以及耐药抗生素的数量。
我们的结果表明,与未治疗组相比,治疗组中ABR基因检测减少的患者百分比更高(减少38.5% vs 0%,P = 0.01)。同样,通过该检测的表型P-AST成分测量,治疗组中耐药抗生素数量减少的患者明显多于未治疗组(减少42.3% vs 8.3%,P = 0.04)。
我们关于耐药基因和表型抗生素敏感性结果均表明,在泌尿外科环境中,基于快速且灵敏的M-PCR/P-AST进行治疗可使疑似复杂性UTI(cUTI)的有症状患者的抗生素耐药性降低而非诱导产生耐药性,这表明此类检测在这类患者的管理中具有重要价值。有必要进一步研究基因减少的原因,包括携带ABR基因细菌的清除和ABR基因的丢失。